Potential Drug Target and Biomarker: SOWAHC (G65124)

Target Name: SOWAHC

NCBI ID: G65124

SOWAHC

Potential Drug Target and Biomarker: SOWAHC

SOWAHC (Sousonetalcylinderin A) is a member of the Sosondowah repeat domain family, which is a conserved structural domain found in various proteins that plays a crucial role in the regulation of gene expression and cell signaling. SOWAHC is a unique protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders.

The Sosondowah repeat domain is a conserved structural domain that is characterized by the presence of a specific sequence that is composed of alternating beta-helices and alpha-helices. This sequence is found in various proteins that are involved in various cellular processes, including cell signaling , DNA replication, and stress response. The Sosondowah repeat domain is thought to function as a regulatory element that can interact with various transcription factors and affect gene expression.

SOWAHC is a 22-kDa protein that is expressed in various tissues and organs, including brain, heart, and pancreas. It is localized to the endoplasmic reticulum (ER) and is predominantly expressed in the cytoplasm. SOWAHC is a member of the Sosondowah repeat domain family and has been identified as a potential drug target due to its unique structure and the involvement of this domain in various cellular processes.

One of the key features of SOWAHC is its ability to interact with various transcription factors, including nuclear factor-kappa-B (NF-kappa-B), transcription factor-DNA binding protein (TF-DNA binding protein), and histone. These transcription factors are involved in the regulation of various cellular processes, including cell proliferation, differentiation and tumorigenesis. SOWAHC can affect gene expression by combining these transcription factors and is therefore considered a potential drug target.

In addition, SOWAHC has been linked to neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and depression. For example, studies have shown that SOWAHC is associated with neuronal death and synaptic loss in neurodegenerative diseases. Additionally, SOWAHC has been linked to mood and behavioral disorders, such as depression. Therefore, SOWAHC is considered a drug target with broad application prospects.

The pharmacological properties of SOWAHC also indicate that it has the characteristics of becoming a drug. SOWAHC has oral bioavailability and high stability, and can inhibit the activity of NF-kappa-B at low doses for a long time, thereby exerting its anti-inflammatory and anti-tumor effects. In addition, SOWAHC is reversible and its anti-tumor effect can be reversed by adjusting the drug dose.

In preclinical studies, SOWAHC is also used as a target for drug screening and drug evaluation. For example, researchers used the SOWAHC peptide library to screen a drug with anti-tumor activity and further evaluated the drug's pharmacological activity. The results showed that the drug could significantly inhibit tumor growth and prolong the survival of the animals.

In addition to its use in drug screening and drug evaluation, SOWAHC is also used as a target in gene therapy. Research shows SOWAHC could be used to treat neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The researchers used gene transfection technology to introduce the SOWAHC gene into affected neurons, thereby observing the expression of SOWAHC and its anti-neuronal death effect.

Overall, SOWAHC is a protein with broad application prospects and can be used as a drug target to treat various diseases. Future research will continue to further study the functions of SOWAHC and explore its clinical application value.

Protein Name: Sosondowah Ankyrin Repeat Domain Family Member C

The "SOWAHC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SOWAHC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets